Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
RecruitingNCT06780670
Novartis PharmaceuticalsProstate Cancer
Start: 2025-02-27End: 2033-07-19Target: 443Updated: 2026-03-23